Suggestions
Farnaz Behroozi, Ph.D.
Biopharma & Digital-First Care Delivery Enthusiast
Farnaz Behroozi, Ph.D. is a seasoned professional in the life sciences and healthcare industry, currently serving as the Global Head of Pharma at Huma, a position she has held since October 2023.12 She is known for her expertise in biopharma and digital-first care delivery.1
Dr. Behroozi has an impressive educational background, including:
- Executive MBA from London Business School (2025)2
- Ph.D. in Bioengineering and Biomedical Engineering from Sharif University of Technology (2018)2
- Joint Ph.D. in Bioengineering and Biomedical Engineering from EPFL (2014-2016)2
- Master of Engineering in BME from UC Irvine (2010-2012)2
- Master of Science in Physics from the University of California, Riverside (2010)2
Her career trajectory includes notable positions such as:
- Project Leader at Boston Consulting Group (BCG) (2022-2023)1
- Management Consultant at Deloitte (2019-2022)1
- Consultant at McKinsey & Company (2018-2019)1
- Scientist at EPFL and UC Irvine (2010-2015)1
Dr. Behroozi specializes in addressing healthcare challenges through innovative solutions, collaborating with clients globally in the pharmaceutical and healthcare sectors. Her expertise extends to corporate and business unit strategy, digital transformation, big data strategy, and organizational model redesign.
Recently, Dr. Behroozi has been actively involved in discussions about advancing healthcare through AI, as evidenced by her participation in the Abu Dhabi Finance Week (ADFW) 2024.3 She has also represented Huma at the World Economic Forum's Annual Meeting of the New Champions, engaging in discussions about healthcare innovation and AI.56
Under her leadership, Huma successfully completed a Series D funding round in July 2024, raising over $80 million and bringing the company's total funding to more than $300 million.4 This achievement underscores Dr. Behroozi's significant role in driving growth and innovation in digital health and AI-driven healthcare solutions.
Highlights
Just one month ago, we at Huma proudly unveiled our Series D funding round and the revolutionary Huma Cloud Platform.
In just 48 hours, nearly 80 trailblazers from life sciences, healthcare, startups, and academia rushed to join the waiting list for the Huma Cloud Beta. Fast forward three weeks, and that number soared past 200.
Today, we're thrilled to announce the launch of the Huma Cloud Workspace, now live with our first wave of handpicked customers for beta testing. And this is just the beginning—we're gearing up to open our cutting-edge platform to everyone.
Discover how we're set to accelerate the integration of digital and AI into healthcare. Stay tuned for more: https://workspace.huma.com
Dan Vahdat Dr Mert Aral Milano Fili Kaushik Gune Hanno Härtlein Tobias Alpsten Dan Martin
We are excited to announce our partnership with Eczacıbaşı Topluluğu Evital, the leading health ecosystem in Türkiye. Through our unique collaboration, Evital will utilize the Huma Cloud Platform to enhance its existing health solutions and expand its offerings to patients and healthcare professionals in Türkiye.
The Huma Cloud Platform utilizes a versatile, regulatory-compliant software development kit (SDK) that features an extensive library of pre-built modules and device connectivity options. It also supports the hosting and deployment of diagnostic and predictive AI/ML models.
Dan Vahdat our Founder & CEO, said: "Over the past decade, we have dedicated ourselves to developing Huma Cloud Platform, a highly configurable, flexible, disease-agnostic, and regulated technology platform. I take pride in the fact that Huma is partnering with Eczacıbaşı Evital to leverage our platform, bringing digital health solutions to Türkiye and supporting individuals in Türkiye to lead longer, fuller lives.”
Read more: https://lnkd.in/e-gYUADD
Register your interest for access to the Huma Cloud Platform: https://lnkd.in/enw8hEVx
